突变KRAS疫苗在高风险人群中拦截胰腺癌的首个人体试验
该I期首个人体研究在20例遗传性胰腺癌易感且影像学胰腺异常的个体中评估了靶向6种常见KRAS突变的肽疫苗(mKRAS-VAX)的安全性、免疫原性和T细胞持久性。不良事件为1-2级,18/20例(90%)产生显著mKRAS特异性T细胞反应,疫苗诱导的克隆型持续长达2年,中位随访16.5个月无胰腺癌发生。
要点
- mKRAS-VAX在遗传性胰腺癌高风险人群中安全性良好,不良事件为1-2级。
- 18/20例(90%)受试者产生显著mKRAS特异性T细胞反应。
- 疫苗诱导的mKRAS特异性T细胞克隆型持续长达2年。
核心结论
- mKRAS-VAX安全且可产生持久的T细胞反应,支持推进mKRAS靶向疫苗用于胰腺癌拦截。
研究设计与样本
- I期首个人体研究,纳入20例遗传性胰腺癌易感且影像学胰腺异常的个体(NCT05013216),评估安全性、免疫原性和T细胞持久性。
主要发现
- 不良事件为1-2级。
- 18/20例(90%)参与者产生显著mKRAS特异性T细胞反应。
- 纵向TCR测序显示疫苗诱导的mKRAS特异性克隆型持续长达2年。
- 中位随访16.5个月期间无参与者发生胰腺导管腺癌(PDAC)。
临床怎么用
- 在高风险人群中,mKRAS-VAX具有良好的安全性和免疫原性,支持进一步开展mKRAS靶向疫苗拦截胰腺癌的临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic ductal adenocarcinoma (PDAC) arises from precursor lesions over a decade-plus, offering a window for interception in high-risk individuals, but current surveillance detects a minority of precursors. Mutant KRAS (mKRAS) is present in most PDACs and their precursors, making it an appealing target for immune-based interception. We conducted a phase I, first-in-human study of a peptide vaccine targeting six common KRAS mutations (mKRAS-VAX) in 20 individuals with hereditary PDAC predisposition and a radiographic pancreatic abnormality (NCT05013216) to assess safety, immunogenicity, and T cell persistence. Adverse events were grade 1-2. Vaccination elicited a significant mKRAS-specific T cell response in 18/20 participants (90%). Longitudinal TCR sequencing demonstrated persistence of vaccine-induced mKRAS-specific clonotypes for up to 2 years. Over a median follow-up of 16.5 months, no participants developed PDAC. These findings demonstrate that mKRAS-VAX is safe and generates durable T cell responses, which support the advancement of mKRAS-targeted vaccination for PDAC interception.
引用
- Haldar SD, Huff AL, Wang HH, et al. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Cancer Discov. 2026. PMID: 42458705. doi:10.1158/2159-8290.CD-25-2245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。